CRL monthly performance report
Monthly CRL research: returns, drawdown, relative strength, seasonality, and key stats.
CRL monthly report
—
Key takeaways
- Charles River Laboratories (CRL) closed August 2026 at $260.72, up 12.13% for the month and +55.66% over the trailing 12 months.
- Year-to-date, CRL is +30.70%, outperforming the S&P 500 which has returned +12.89% YTD.
- The stock is trading +38.72% versus its 200-day moving average ($187.94), a bullish technical signal.
- Over the past three years, CRL has underperformed the S&P 500 by −46.27%, with a relative strength index reading of 74.4.
- Win rate over the trailing 39 months stands at 48.7% — 19 positive months versus 20 negative months.
Charles River Laboratories ended August 2026 at $260.72, posting a monthly return of +12.13%. The S&P 500 returned +3.05% over the same window, leaving relative performance at +9.09%.
The current quarter stands at +14.66% (Q3 2026 (QTD)), while medium-term trend remains constructive: price is +38.72% versus the 200-day moving average ($187.94).
Year-to-date, CRL is +30.70% against SPY +12.89%, a gap of +17.81%. The stock is currently −1.98% below its 52-week high, with maximum 3-year drawdown at −63.52%.
| Period | CRL | S&P 500 (SPY) | Excess return |
|---|---|---|---|
| 1 Day | +11.36% | −0.20% | +11.56% |
| 1 Week | +8.44% | +3.90% | +4.53% |
| 1 Month | +12.13% | +3.05% | +9.09% |
| 3 Months | +56.15% | +7.11% | +49.03% |